Company Overview
Snapshot
Founded in January 2017 by Bentzi Gruber, Guy Zur, Gerry Waintraub, and Taire Rubin, GWave operates with 1–10 employees. The company has raised $21.1M across three funding rounds. In August 2023, GWave closed a Series C funding round, coinciding with the unveiling of new clinical data for its GWave technology.
Business overview
GWave, developed by Hagar Technology, specializes in noninvasive glucose monitoring within the Health Tech & Life Sciences sector. The company's core product is a glucometer that uses radio frequency waves and proprietary AI algorithms to continuously measure blood glucose levels in real time. This technology is designed to be cost-efficient, compact, and highly accurate, serving the digital healthcare and medical devices markets. GWave connects seamlessly to Bluetooth and smartphones, offering a user-friendly experience with automated alarms and cloud-based data storage for users, caretakers, and medical professionals.
Strategic signal
In August 2023, GWave unveiled new clinical data for its groundbreaking GWave technology, coinciding with the closing of its Series C funding round. This development is significant as it provides validation for the company's non-invasive glucose monitoring solution, potentially accelerating its path to market and demonstrating its readiness for broader adoption in the diabetes management landscape. For investors, this signals strong progress in product development and commercialization, reinforcing confidence in GWave's innovative approach to health tech.
Log in to access full profile ›Company Intelligence Q&A
- What is GWave's primary product?
- GWave's primary product is a noninvasive glucometer that utilizes radio frequency waves and proprietary AI algorithms to continuously measure blood glucose levels in real time, offering a cost-efficient, compact, and accurate monitoring solution.
- When was GWave awarded FDA Breakthrough Device Designation?
- In November 2021, HAGAR GWave was awarded FDA Breakthrough Device Designation, recognizing the potential of its technology to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
- What was the most recent funding event for GWave?
- In August 2023, GWave closed a Series C funding round, securing $5 million. This funding coincided with the unveiling of new clinical data on its GWave technology.
- Which investor participated in GWave's Series B funding round?
- In August 2021, Columbia Pacific Capital Partners led GWave's Series B funding round.
- When did GWave present at a global diabetes conference?
- In April 2022, GWave by HAGAR presented at a renowned global diabetes conference, showcasing its non-invasive blood glucose monitor data following its FDA breakthrough device designation.